Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Qβ virus-like particles.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
06 Oct 2023
06 Oct 2023
Historique:
received:
23
06
2023
accepted:
15
09
2023
medline:
7
10
2023
pubmed:
7
10
2023
entrez:
6
10
2023
Statut:
epublish
Résumé
A maternal vaccine to protect neonates against Group B Streptococcus invasive infection is an unmet medical need. Such a vaccine should ideally be offered during the third trimester of pregnancy and induce strong immune responses after a single dose to maximize the time for placental transfer of protective antibodies. A key target antigen is the capsular polysaccharide, an anti-phagocytic virulence factor that elicits protective antibodies when conjugated to carrier proteins. The most prevalent polysaccharide serotypes conjugated to tetanus or diphtheria toxoids have been tested in humans as monovalent and multivalent formulations, showing excellent safety profiles and immunogenicity. However, responses were suboptimal in unprimed individuals after a single shot, the ideal schedule for vaccination during the third trimester of pregnancy. In the present study, we obtained and optimized self-assembling virus-like particles conjugated to Group B Streptococcus capsular polysaccharides. The resulting glyco-nanoparticles elicited strong immune responses in mice already after one immunization, providing pre-clinical proof of concept for a single-dose vaccine.
Identifiants
pubmed: 37803013
doi: 10.1038/s41541-023-00744-5
pii: 10.1038/s41541-023-00744-5
pmc: PMC10558462
doi:
Types de publication
Journal Article
Langues
eng
Pagination
152Informations de copyright
© 2023. Springer Nature Limited.
Références
Russell, N. J. et al. Risk of early-onset neonatal group B streptococcal disease with maternal colonization worldwide: systematic review and meta-analyses. Clin. Infect. Dis. 65, S152–S159 (2017).
pubmed: 29117325
pmcid: 5850448
doi: 10.1093/cid/cix655
Lawn, J. E. et al. Group B streptococcal disease worldwide for pregnant women, stillbirths, and children: why, what, and how to undertake estimates? Clin. Infect. Dis. 65, S89–S99 (2017).
pubmed: 29117323
pmcid: 5850012
doi: 10.1093/cid/cix653
Madrid, L. et al. Infant group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin. Infect. Dis. 65, S160–S172 (2017).
pubmed: 29117326
pmcid: 5850457
doi: 10.1093/cid/cix656
Schrag, S. J. & Verani, J. R. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: Experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine 31, D20–D26 (2013).
pubmed: 23219695
doi: 10.1016/j.vaccine.2012.11.056
Kobayashi, M. et al. WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016. Vaccine 37, 7307–7314 (2019).
pubmed: 28017431
pmcid: 6892266
doi: 10.1016/j.vaccine.2016.12.029
Nishihara, Y., Dangor, Z., French, N., Madhi, S. & Heyderman, R. Challenges in reducing group B Streptococcus disease in African settings. Arch. Dis. Child. 102, 72–77 (2017).
pubmed: 27831912
doi: 10.1136/archdischild-2016-311419
Cieslewicz, M. J. et al. Structural and genetic diversity of group B Streptococcus capsular polysaccharides. Infect. Immun. 73, 3096–3103 (2005).
pubmed: 15845517
pmcid: 1087335
doi: 10.1128/IAI.73.5.3096-3103.2005
Berti, F. et al. Structure of the type IX group B Streptococcus capsular polysaccharide and its evolutionary relationship with types V and VII. J. Biol. Chem. 289, 23437–23448 (2014).
pubmed: 24990951
pmcid: 4156066
doi: 10.1074/jbc.M114.567974
Paoletti, L. C. et al. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 62, 3236–3243 (1994).
pubmed: 8039893
pmcid: 302951
doi: 10.1128/iai.62.8.3236-3243.1994
Baker, C. J. & Kasper, D. L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N. Engl. J. Med. 294, 753–756 (1976).
pubmed: 768760
doi: 10.1056/NEJM197604012941404
Baker, C. J. Group B streptococcal conjugate vaccines. Arch. Dis. Child. 88, 375–378 (2003).
pubmed: 12716700
pmcid: 1719562
doi: 10.1136/adc.88.5.375
Fabbrini, M. et al. Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women. J. Infect. 76, 449–456 (2018).
pubmed: 29374589
doi: 10.1016/j.jinf.2018.01.006
Paoletti, L. C. et al. Effects of alum adjuvant or a booster dose on immunogenicityduring clinical trials of group B streptococcal type III conjugate vaccines. Infect. Immun. 70, 426–426 (2002).
pmcid: 127651
doi: 10.1128/IAI.70.1.426-426.2002
Madhi, S. A. et al. Safety and immunogenicity of an investigational maternal trivalent group B Streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect. Dis. 16, 923–934 (2016).
pubmed: 27139805
doi: 10.1016/S1473-3099(16)00152-3
Madhi, S. A. et al. Antibody kinetics and response to routine vaccinations in infants born to women who received an investigational trivalent group B Streptococcus polysaccharide CRM197-conjugate vaccine during pregnancy. Clin. Infect. Dis. 65, 1897–1904 (2017).
pubmed: 29029127
pmcid: 5848233
doi: 10.1093/cid/cix666
Beran, J. et al. Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B Streptococcus vaccine in healthy non-pregnant women: results from a randomized comparative phase II trial. Vaccine 38, 3227–3234 (2020).
pubmed: 32169390
doi: 10.1016/j.vaccine.2020.02.085
Absalon, J. et al. Safety and immunogenicity of a novel hexavalent group B Streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. Lancet Infect. Dis. 21, 263–274 (2021).
pubmed: 32891191
doi: 10.1016/S1473-3099(20)30478-3
Leroux-Roels, G. et al. A randomized, observer-blind phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women. Vaccine 34, 1786–1791 (2016).
pubmed: 26928074
doi: 10.1016/j.vaccine.2016.02.044
Leroux-Roels, G. et al. Safety and immunogenicity of a second dose of an investigational maternal trivalent group B Streptococcus vaccine in nonpregnant women 4–6 years after a first dose: results from a phase 2 trial. Clin. Infect. Dis. 70, 2570–2579 (2020).
pubmed: 31394574
doi: 10.1093/cid/ciz737
Margarit, I. et al. Preventing bacterial infections with pilus-based vaccines: the group B Streptococcus Paradigm. J. Infect. Dis. 199, 108–115 (2009).
pubmed: 19086816
doi: 10.1086/595564
Stålhammar-Carlemalm, M., Waldemarsson, J., Johnsson, E., Areschoug, T. & Lindahl, G. Nonimmunodominant regions are effective as building blocks in a streptococcal fusion protein vaccine. Cell Host Microbe 2, 427–434 (2007).
pubmed: 18078694
doi: 10.1016/j.chom.2007.10.003
Gonzalez-Miro, M. et al. Safety and immunogenicity of the group B Streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial. iScience 26, 106261 (2023).
pubmed: 36915681
pmcid: 10005905
doi: 10.1016/j.isci.2023.106261
López-Sagaseta, J., Malito, E., Rappuoli, R. & Bottomley, M. J. Self-assembling protein nanoparticles in the design of vaccines. Comput. Struct. Biotechnol. J. 14, 58–68 (2016).
pubmed: 26862374
doi: 10.1016/j.csbj.2015.11.001
Kang, S.-M., Kim, M.-C. & Compans, R. W. Virus-like particles as universal influenza vaccines. Expert Rev. Vaccines 11, 995–1007 (2012).
pubmed: 23002980
pmcid: 3513402
doi: 10.1586/erv.12.70
Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102–106 (2013).
pubmed: 23698367
pmcid: 8312026
doi: 10.1038/nature12202
He, L. et al. Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat. Commun. 7, 12041 (2016).
pubmed: 27349934
pmcid: 4931238
doi: 10.1038/ncomms12041
Marcandalli, J. et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420–1431.e17 (2019).
pubmed: 30849373
pmcid: 6424820
doi: 10.1016/j.cell.2019.01.046
Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367–1382.e17 (2020).
pubmed: 33160446
pmcid: 7604136
doi: 10.1016/j.cell.2020.10.043
Zhang, B. et al. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Sci. Rep. 10, 18149 (2020).
pubmed: 33097791
pmcid: 7584627
doi: 10.1038/s41598-020-74949-2
Fougeroux, C. et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nat. Commun. 12, 324 (2021).
pubmed: 33436573
pmcid: 7804149
doi: 10.1038/s41467-020-20251-8
Wang, L., Xing, D., Le Van, A., Jerse, A. E. & Wang, S. Structure‐based design of ferritin nanoparticle immunogens displaying antigenic loops of Neisseria gonorrhoeae. FEBS Open Bio 7, 1196–1207 (2017).
pubmed: 28781959
pmcid: 5537070
doi: 10.1002/2211-5463.12267
Aston-Deaville, S. et al. An assessment of the use of Hepatitis B Virus core protein virus-like particles to display heterologous antigens from Neisseria meningitidis. Vaccine 38, 3201–3209 (2020).
pubmed: 32178907
pmcid: 7113836
doi: 10.1016/j.vaccine.2020.03.001
Cappelli, L. et al. Self-assembling protein nanoparticles and virus like particles correctly display β-barrel from meningococcal factor H-binding protein through genetic fusion. PLoS ONE 17, e0273322 (2022).
pubmed: 36112575
pmcid: 9480994
doi: 10.1371/journal.pone.0273322
Veggi, D. et al. Effective multivalent oriented presentation of meningococcal NadA antigen trimers by self-assembling ferritin nanoparticles. Int. J. Mol. Sci. 24, 6183 (2023).
pubmed: 37047152
pmcid: 10093968
doi: 10.3390/ijms24076183
Polonskaya, Z. et al. T cells control the generation of nanomolar-affinity anti-glycan antibodies. J. Clin. Invest. 127, 1491–1504 (2017).
pubmed: 28287405
pmcid: 5373877
doi: 10.1172/JCI91192
Li, X. et al. Orthogonal modular biosynthesis of nanoscale conjugate vaccines for vaccination against infection. Nano Res. 15, 1645–1653 (2022).
pubmed: 34405037
doi: 10.1007/s12274-021-3713-4
Wessels, M. R. et al. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J. Clin. Invest. 86, 1428–1433 (1990).
pubmed: 2243123
pmcid: 296886
doi: 10.1172/JCI114858
Paoletti, L. C., Kennedy, R. C., Chanh, T. C. & Kasper, D. L. Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons. Infect. Immun. 64, 677–679 (1996).
pubmed: 8550227
pmcid: 173821
doi: 10.1128/iai.64.2.677-679.1996
Rodrigues, M. Q., Alves, P. M. & Roldão, A. Functionalizing ferritin nanoparticles for vaccine development. Pharmaceutics 13, 1621 (2021).
pubmed: 34683914
pmcid: 8540537
doi: 10.3390/pharmaceutics13101621
Hsia, Y. et al. Design of a hyperstable 60-subunit protein icosahedron. Nature 535, 136–139 (2016).
pubmed: 27309817
pmcid: 4945409
doi: 10.1038/nature18010
Chang, J., Gorzelnik, K. V., Thongchol, J. & Zhang, J. Structural assembly of Qβ virion and its diverse forms of virus-like particles. Viruses 14, 225 (2022).
pubmed: 35215818
pmcid: 8880383
doi: 10.3390/v14020225
Akache, B. et al. Anti-IgE Qb-VLP conjugate vaccine self-adjuvants through activation of TLR7. Vaccines 4, 3 (2016).
pubmed: 26805897
pmcid: 4810055
doi: 10.3390/vaccines4010003
Fiedler, J. D., Brown, S. D., Lau, J. L. & Finn, M. G. RNA-directed packaging of enzymes within virus-like particles. Angew. Chem. Int. Ed. 49, 9648–9651 (2010).
doi: 10.1002/anie.201005243
Tariq, H., Batool, S., Asif, S., Ali, M. & Abbasi, B. H. Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases. Front. Microbiol. 12, 790121 (2022).
pubmed: 35046918
pmcid: 8761975
doi: 10.3389/fmicb.2021.790121
Fang, P., Bowman, J. C., Gómez Ramos, L. M., Hsiao, C. & Williams, L. D. RNA: packaged and protected by VLPs. RSC Adv. 8, 21399–21406 (2018).
pubmed: 35539947
pmcid: 9080931
doi: 10.1039/C8RA02084A
Carboni, F., Cozzi, R., Margarit, I., Romagnoli, G. & Romano, M. R. Bacterial immunization using qbeta hairpin nanoparticle constructs. WO/2023/111826 (2023).
Pan, J. & Cui, Z. Self‐assembled nanoparticles: exciting platforms for vaccination. Biotechnol. J. 15, 2000087 (2020).
doi: 10.1002/biot.202000087
Kheirollahpour, M., Mehrabi, M., Dounighi, N. M., Mohammadi, M. & Masoudi, A. Nanoparticles and vaccine development. Pharm. Nanotechnol. 8, 6–21 (2020).
pubmed: 31647394
doi: 10.2174/2211738507666191024162042
Micoli, F., Adamo, R. & Costantino, P. Protein carriers for glycoconjugate vaccines: history, selection criteria, characterization and new trends. Molecules 23, 1451 (2018).
pubmed: 29914046
pmcid: 6100388
doi: 10.3390/molecules23061451
Cornuz, J. et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 3, e2547 (2008).
pubmed: 18575629
pmcid: 2432028
doi: 10.1371/journal.pone.0002547
Tissot, A. C. et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371, 821–827 (2008).
pubmed: 18328929
doi: 10.1016/S0140-6736(08)60381-5
Bachmann, M. F. & Jennings, G. T. Therapeutic vaccines for chronic diseases: successes and technical challenges. Philos. Trans. R. Soc. B Biol. Sci. 366, 2815–2822 (2011).
doi: 10.1098/rstb.2011.0103
Huang, X., Wang, X., Zhang, J., Xia, N. & Zhao, Q. Escherichia coli-derived virus-like particles in vaccine development. npj Vaccines 2, 1–8 (2017).
doi: 10.1038/s41541-017-0006-8
C. Gomes, A., Roesti, E. S., El-Turabi, A. & Bachmann, M. F. Type of RNA packed in VLPs impacts IgG class switching—implications for an influenza vaccine design. Vaccines 7, 47 (2019).
pubmed: 31167472
pmcid: 6630894
doi: 10.3390/vaccines7020047
Hong, S. et al. B cells are the dominant antigen-presenting cells that activate naive CD4+ T cells upon immunization with a virus-derived nanoparticle antigen. Immunity 49, 695–708.e4 (2018).
pubmed: 30291027
doi: 10.1016/j.immuni.2018.08.012
Hung, P. P., Ling, C. M. & Overby, L. R. Self-assembly of Qβ and MS2 phage particles: possible function of initiation complexes. Science 166, 1638–1640 (1969).
pubmed: 5360586
doi: 10.1126/science.166.3913.1638
Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526–1529 (2004).
pubmed: 14976262
doi: 10.1126/science.1093620
Rhee, J.-K. et al. Colorful virus-like particles: fluorescent protein packaging by the Qβ capsid. Biomacromolecules 12, 3977–3981 (2011).
pubmed: 21995513
pmcid: 3246388
doi: 10.1021/bm200983k
Fang, P.-Y. et al. Functional RNAs: combined assembly and packaging in VLPs. Nucleic Acids Res. 45, 3519–3527 (2017).
pubmed: 27903913
doi: 10.1093/nar/gkw1154
Horn, W. T. et al. Structural basis of RNA binding discrimination between bacteriophages Qβ and MS2. Structure 14, 487–495 (2006).
pubmed: 16531233
pmcid: 7612262
doi: 10.1016/j.str.2005.12.006
Pulendran, B., S. Arunachalam, P. & O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).
pubmed: 33824489
pmcid: 8023785
doi: 10.1038/s41573-021-00163-y
Phares, T. W. et al. Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes. Malar. J. 16, 115 (2017).
pubmed: 28288639
pmcid: 5347822
doi: 10.1186/s12936-017-1766-3
Adamo, R., Carboni, F., Cozzi, R., Margarit, I. & Romano, M. R. Bacterial immunization using nanoparticle vaccine. WO/2021/250628 (2021).
Buffi, G. et al. Novel multiplex immunoassays for quantification of IgG against group B Streptococcus capsular polysaccharides in human sera. mSphere 4, 1–15 (2019).
doi: 10.1128/mSphere.00273-19
Fabbrini, M. et al. A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against group B Streptococcus. J. Immunol. Methods 378, 11–19 (2012).
pubmed: 22309986
doi: 10.1016/j.jim.2012.01.011
Bieging, K. T. et al. Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae. Clin. Vaccin. Immunol. 12, 1238–1242 (2005).
doi: 10.1128/CDLI.12.10.1238-1242.2005
Mountzouros, K. T. & Howell, A. P. Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis. J. Clin. Microbiol. 38, 2878–2884 (2000).
pubmed: 10921943
pmcid: 87135
doi: 10.1128/JCM.38.8.2878-2884.2000